Univariate analysis of genetic alterations and clinical characteristics.

EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.*Cohort 1 (1772 patients with lung adenocarcinoma) testing of EGFR, KRAS, HER2 and BRAF mutations.**Cohort 2 (295 patients with EGFR-wild type lung adenocarcinoma) testing of EML4-ALK translocation.#Exclude 12 patients of cohort 1 and 1 patients of cohort 2 with incomplete data on tumor staging For KRAS mutations, a significantly higher mutation rate was noted in male then in female patients (9.3 vs. 1.8%, P KRAS mutation. For HER2 mutations, patients with more advanced diseases were associated with a higher mutation rate (2.6% in stage IIIb-IV vs. 0.8% in stage I-IIIa, P = 0.015). For BRAF mutation, there was no significant association between patient characteristics and the mutation rate.Univariate analysis of genetic alterations and clinical characteristics.